NCT01097369View on ClinicalTrials.gov

Elitek (Rasburicase) Immuno-Monitoring Study

TerminatedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Tumor Lysis Syndrome
Trial Locations (4)

10595

Investigational Site Number 3, Valhalla

38105

Investigational Site Number 2, Memphis

73104

Investigational Site Number 4, Oklahoma City

77030

Investigational Site Number 1, Houston

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY